Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 8/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PLAT | P00750 | 6/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3868513 | 0.87 | NMT1 (0.55) | NMT1NR1H4PLAT | |
| Hydrochloric Acid SCHEMBL3597129 | 0.86 | NMT1 (0.54) | NMT1NR1H4PLAT | |
| SCHEMBL27755012 | 0.86 | CYP2C19 (0.58) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5634822 | 0.85 | PLAT (0.52) | NMT1NR1H4PLAT | |
| SCHEMBL3525267 | 0.84 | PPARA (0.45) | NMT1NR1H4PLAT | |
| SCHEMBL13547434 | 0.82 | PLAT (0.41) | NMT1NR1H4PLAT | |
| SCHEMBL3530200 | 0.82 | NMT1 (0.51) | NMT1NR1H4 | |
| Hydrochloric Acid SCHEMBL3601850 | 0.81 | PLAT (0.41) | NMT1NR1H4PLAT | |
| SCHEMBL3595132 | 0.80 | PLAT (0.43) | NMT1NR1H4PLAT | |
| SCHEMBL13543048 | 0.80 | PLAT (0.41) | NMT1NR1H4PLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101420941-A | Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, and related combination therapies | ARENA PHARM INC (US) | 2009-04-29 | — | — | CN | disclosed |
| CN-101332303-A | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level | ARENA PHARM INC (US) | 2008-12-31 | — | — | CN | disclosed |